Related references
Note: Only part of the references are listed.NF-kappa B activation impairs somatic cell reprogramming in ageing (Publication with Expression of Concern. See vol. 21, pg. 410, 2019)
Clara Soria-Valles et al.
NATURE CELL BIOLOGY (2015)
Impact of Farnesylation Inhibitors on Survival in Hutchinson-Gilford Progeria Syndrome
Leslie B. Gordon et al.
CIRCULATION (2014)
Induced Pluripotent Stem Cells Reveal Functional Differences Between Drugs Currently Investigated in Patients With Hutchinson-Gilford Progeria Syndrome
Sophie Blondel et al.
STEM CELLS TRANSLATIONAL MEDICINE (2014)
Synthesis of Methoxy-substituted Chalcones and in vitro Evaluation of their Anticancer Potential
Kannatt Radhakrishnan Ethiraj et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2013)
Defective Extracellular Pyrophosphate Metabolism Promotes Vascular Calcification in a Mouse Model of Hutchinson-Gilford Progeria Syndrome That Is Ameliorated on Pyrophosphate Treatment
Ricardo Villa-Bellosta et al.
CIRCULATION (2013)
N6-isopentenyladenosine improves nuclear shape in fibroblasts from humans with progeroid syndromes by inhibiting the farnesylation of prelamin A
Maurizio Bifulco et al.
FEBS JOURNAL (2013)
Thienopyrimidine Bisphosphonate (ThPBP) Inhibitors of the Human Farnesyl Pyrophosphate Synthase: Optimization and Characterization of the Mode of Inhibition
Chun Yuen Leung et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Identification of small molecules for human hepatocyte expansion and iPS differentiation
Jing Shan et al.
NATURE CHEMICAL BIOLOGY (2013)
Adapting human pluripotent stem cells to high-throughput and high-content screening
Sabrina C. Desbordes et al.
NATURE PROTOCOLS (2013)
Phenotypic Screening with Human iPS Cell-Derived Cardiomyocytes: HTS-Compatible Assays for Interrogating Cardiac Hypertrophy
Coby Carlson et al.
JOURNAL OF BIOMOLECULAR SCREENING (2013)
Discovery of Kinase Spectrum Selective Macrocycle (16E)-14-Methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a Potent Inhibitor of Cyclin Dependent Kinases (CDKs), Janus Kinase 2 (JAK2), and Fms-like Tyrosine Kinase-3 (FLT3) for the Treatment of Cancer
Anthony D. William et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Potent and Selective Aminopyrimidine-Based B-Raf Inhibitors with Favorable Physicochemical and Pharmacokinetic Properties
Simon Mathieu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Large-scale screening using familial dysautonomia induced pluripotent stem cells identifies compounds that rescue IKBKAP expression
Gabsang Lee et al.
NATURE BIOTECHNOLOGY (2012)
Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome
Leslie B. Gordon et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
A GAL4-Driver Line Resource for Drosophila Neurobiology
Arnim Jenett et al.
CELL REPORTS (2012)
Design and synthesis of triazolopyridazines substituted with methylisoquinolinone as selective c-Met kinase inhibitors
Jae Wook Ryu et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2011)
Foreword: Bisphosphonates
David Burr et al.
BONE (2011)
A Human iPSC Model of Hutchinson Gilford Progeria Reveals Vascular Smooth Muscle and Mesenchymal Stem Cell Defects
Jinqiu Zhang et al.
CELL STEM CELL (2011)
Recapitulation of premature ageing with iPSCs from Hutchinson-Gilford progeria syndrome
Guang-Hui Liu et al.
NATURE (2011)
Targeting protein prenylation for cancer therapy
Norbert Berndt et al.
NATURE REVIEWS CANCER (2011)
High-content screening of feeder-free human embryonic stem cells to identify pro-survival small molecules
Paul D. Andrews et al.
BIOCHEMICAL JOURNAL (2010)
CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms
Jeffrey W. Tyner et al.
BLOOD (2010)
Assessing the efficacy of protein farnesyltransferase inhibitors in mouse models of progeria
Shao H. Yang et al.
JOURNAL OF LIPID RESEARCH (2010)
A Small Molecule Primes Embryonic Stem Cells for Differentiation
Shoutian Zhu et al.
CELL STEM CELL (2009)
A phase II trial of high-dose imatinib mesylate for relapsed or refractory c-kit positive and Bcr-Abl negative acute myeloid leukaemia: The AFR-15 trial
Patrice Chevallier et al.
LEUKEMIA RESEARCH (2009)
4-amino-6-arylamino-pyrimidine-5-carbaldehyde hydrazones as potent ErbB-2/EGFR dual kinase inhibitors
Guozhang Xu et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2008)
High-throughput screening assay for the identification of compounds regulating self-renewal and differentiation in human embryonic stem cells
Sabrina C. Desbordes et al.
CELL STEM CELL (2008)
QSAR study on tetrahydroquinoline analogues as plasmodium protein farnesyltransferase inhibitors: A comparison of rationales of malarial and mammalian enzyme inhibitory activities for selectivity
Manish K. Gupta et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2008)
Lamin A-dependent misregulation of adult stem cells associated with accelerated ageing
Paola Scaffidi et al.
NATURE CELL BIOLOGY (2008)
Combined treatment with statins and aminobisphosphonates extends longevity in a mouse model of human premature aging
Ignacio Varela et al.
NATURE MEDICINE (2008)
Phenotype and course of Hutchinson-Gilford progeria syndrome
Melissa A. Merideth et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
A novel quinoline, MT477: suppresses cell signaling through Ras molecular pathway, inhibits PKC activity, and demonstrates in vivo anti-tumor activity against human carcinoma cell lines
Piotr Jasinski et al.
INVESTIGATIONAL NEW DRUGS (2008)
Induction of pluripotent stem cells from adult human fibroblasts by defined factors
Kazutoshi Takahashi et al.
CELL (2007)
Efficacy, pharmacokinetics, and metabolism of tetrahydroquinoline inhibitors of Plasmodium falciparum protein farnesyltransferase
Wesley C. Van Voorhis et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
A farnesyltransferase inhibitor improves disease phenotypes in mice with a Hutchinson-Gilford progeria syndrome mutation
Shao H. Yang et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Structural biology of protein farnesyltransferase and geranylgeranyltransferase type I
KT Lane et al.
JOURNAL OF LIPID RESEARCH (2006)
A protein farnesyltransferase inhibitor ameliorates disease in a mouse model of progeria
LG Fong et al.
SCIENCE (2006)
Fighting parasitic disease by blocking protein farnesylation
RT Eastman et al.
JOURNAL OF LIPID RESEARCH (2006)
Incomplete processing of mutant lamin A in Hutchinson-Gilford progeria leads to nuclear abnormalities, which are reversed by farnesyltransferase inhibition
MW Glynn et al.
HUMAN MOLECULAR GENETICS (2005)
Inhibiting farnesylation reverses the nuclear morphology defect in a HeLa cell model for Hutchinson-Gilford progeria syndrome
MP Mallampalli et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells
S Verstovsek et al.
CANCER (2005)
Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome
BC Capell et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Blocking protein farnesyltransferase improves nuclear blebbing in mouse fibroblasts with a targeted Hutchinson-Gilford progeria syndrome mutation
SH Yang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Protein farnesyltransferase inhibitors exhibit potent antimalarial activity
L Nallan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer
E Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Lamin A and ZMPSTE24 (FACE-1) defects cause nuclear disorganization and identify restrictive dermopathy as a lethal neonatal laminopathy
CL Navarro et al.
HUMAN MOLECULAR GENETICS (2004)
Lamin A truncation in Hutchinson-Gilford progeria
A De Sandre-Giovannoli et al.
SCIENCE (2003)
Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome
M Eriksson et al.
NATURE (2003)
Further insight into mechanism of action of clodronate:: Inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite
PP Lehenkari et al.
MOLECULAR PHARMACOLOGY (2002)
Share Paper
